CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) --
Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, will present key data on its amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) programs and on Huntington’s disease at the American Academy of Neurology (AAN) 70th Annual Meeting taking place in Los Angeles from April 21 to April 27, 2018.
The first presentation, entitled "Stereopure Antisense Oligonucleotides Preferentially Knockdown G4C2 Repeat-Containing C9ORF72 Transcripts: A Potential Therapeutic Approach for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)", will be part of the session "Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy", which will take place at 4:45 p.m. PDT on April 23, 2018. The presentation will be given by Dr. Robert H. Brown, Jr., Chair and Professor of Neurology at the University of Massachusetts Medical School.
In January 2017, Wave and the University of Massachusetts Medical School established a collaboration to further understand neurodegenerative and neuromuscular diseases and characterize the pharmacology of oligonucleotides. Research under this collaboration is conducted by Dr. Brown, an internationally known researcher and physician leading basic and clinical research on ALS and other neurodegenerative diseases.
The second presentation, entitled "Frequency of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington's Disease (HD): Results from a Prospective Observational Research Study" (Poster #037), will be presented by Dr. Daniel Claassen, Associate Professor of Neurology at Vanderbilt University, and will be on display during Poster Session P4 between 11:30 a.m. and 7:00 p.m. PDT on April 25, 2018.
About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Its chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. The company’s pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.
Source: Wave Life Sciences